Posted by Michael Wonder on 20 Jul 2026
European Commission approves Jascayd, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
17 July 2026 - Boehringer Ingelheim today announced that the European Commission has granted marketing authorization for Jascayd (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF).
This marks the first new treatment approved in IPF in the EU in over a decade and for PPF in more than five years.
